Target Gene/Pathway Pathway / Gene
Search results
No. | KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related | KEGG GENES | KEGG DRUG | DrugBank | 指定難病告示番号 | ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | African trypanosomiasis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Emapalumab Emapalumab 💬African trypanosomiasis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬1. African trypanosomiasis
|
||||||||||||||||||||||||||||||||
2 | African trypanosomiasis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Fontolizumab Fontolizumab 💬African trypanosomiasis
| Fontolizumab | 046 1件: 46 💬2. African trypanosomiasis
|
||||||||||||||||||||||||||||||||
3 | Allograft rejection 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Emapalumab Emapalumab 💬Allograft rejection
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬3. Allograft rejection
|
||||||||||||||||||||||||||||||||
4 | Allograft rejection 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Fontolizumab Fontolizumab 💬Allograft rejection
| Fontolizumab | 046 1件: 46 💬4. Allograft rejection
|
||||||||||||||||||||||||||||||||
5 | Amoebiasis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Emapalumab Emapalumab 💬Amoebiasis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬5. Amoebiasis
|
||||||||||||||||||||||||||||||||
6 | Amoebiasis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Fontolizumab Fontolizumab 💬Amoebiasis
| Fontolizumab | 046 1件: 46 💬6. Amoebiasis
|
||||||||||||||||||||||||||||||||
7 | Antigen processing and presentation 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Emapalumab Emapalumab 💬Antigen processing and presentation
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬7. Antigen processing and presentation
|
||||||||||||||||||||||||||||||||
8 | Antigen processing and presentation 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Fontolizumab Fontolizumab 💬Antigen processing and presentation
| Fontolizumab | 046 1件: 46 💬8. Antigen processing and presentation
|
||||||||||||||||||||||||||||||||
9 | Chagas disease 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Emapalumab Emapalumab 💬Chagas disease
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬9. Chagas disease
|
||||||||||||||||||||||||||||||||
10 | Chagas disease 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬African trypanosomiasis
|
Fontolizumab Fontolizumab 💬Chagas disease
| Fontolizumab | 046 1件: 46 💬10. Chagas disease
|
||||||||||||||||||||||||||||||||
11 | Chagas disease 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Chagas disease
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬11. Chagas disease
|
||||||||||||||||||||||||||||||||
12 | Cytokine-cytokine receptor interaction 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Cytokine-cytokine receptor interaction
|
Emapalumab Emapalumab 💬Cytokine-cytokine receptor interaction
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬12. Cytokine-cytokine receptor interaction
|
||||||||||||||||||||||||||||||||
13 | Cytokine-cytokine receptor interaction 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Cytokine-cytokine receptor interaction
|
Fontolizumab Fontolizumab 💬Cytokine-cytokine receptor interaction
| Fontolizumab | 046 1件: 46 💬13. Cytokine-cytokine receptor interaction
|
||||||||||||||||||||||||||||||||
14 | Cytokine-cytokine receptor interaction 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Cytokine-cytokine receptor interaction
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬14. Cytokine-cytokine receptor interaction
|
||||||||||||||||||||||||||||||||
15 | Fluid shear stress and atherosclerosis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Emapalumab Emapalumab 💬Fluid shear stress and atherosclerosis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬15. Fluid shear stress and atherosclerosis
|
||||||||||||||||||||||||||||||||
16 | Fluid shear stress and atherosclerosis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Fontolizumab Fontolizumab 💬Fluid shear stress and atherosclerosis
| Fontolizumab | 046 1件: 46 💬16. Fluid shear stress and atherosclerosis
|
||||||||||||||||||||||||||||||||
17 | Graft-versus-host disease 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Emapalumab Emapalumab 💬Graft-versus-host disease
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬17. Graft-versus-host disease
|
||||||||||||||||||||||||||||||||
18 | Graft-versus-host disease 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Fontolizumab Fontolizumab 💬Graft-versus-host disease
| Fontolizumab | 046 1件: 46 💬18. Graft-versus-host disease
|
||||||||||||||||||||||||||||||||
19 | Hepatitis C 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Emapalumab Emapalumab 💬Hepatitis C
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬19. Hepatitis C
|
||||||||||||||||||||||||||||||||
20 | Hepatitis C 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Fontolizumab Fontolizumab 💬Hepatitis C
| Fontolizumab | 046 1件: 46 💬20. Hepatitis C
|
||||||||||||||||||||||||||||||||
21 | Herpes simplex virus 1 infection 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Emapalumab Emapalumab 💬Herpes simplex virus 1 infection
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬21. Herpes simplex virus 1 infection
|
||||||||||||||||||||||||||||||||
22 | Herpes simplex virus 1 infection 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Fluid shear stress and atherosclerosis
|
Fontolizumab Fontolizumab 💬Herpes simplex virus 1 infection
| Fontolizumab | 046 1件: 46 💬22. Herpes simplex virus 1 infection
|
||||||||||||||||||||||||||||||||
23 | Herpes simplex virus 1 infection 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Herpes simplex virus 1 infection
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬23. Herpes simplex virus 1 infection
|
||||||||||||||||||||||||||||||||
24 | HIF-1 signaling pathway 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬HIF-1 signaling pathway
|
Emapalumab Emapalumab 💬HIF-1 signaling pathway
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬24. HIF-1 signaling pathway
|
||||||||||||||||||||||||||||||||
25 | HIF-1 signaling pathway 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬HIF-1 signaling pathway
|
Fontolizumab Fontolizumab 💬HIF-1 signaling pathway
| Fontolizumab | 046 1件: 46 💬25. HIF-1 signaling pathway
|
||||||||||||||||||||||||||||||||
26 | HIF-1 signaling pathway 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬HIF-1 signaling pathway
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬26. HIF-1 signaling pathway
|
||||||||||||||||||||||||||||||||
27 | IL-17 signaling pathway 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬IL-17 signaling pathway
|
Emapalumab Emapalumab 💬IL-17 signaling pathway
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬27. IL-17 signaling pathway
|
||||||||||||||||||||||||||||||||
28 | IL-17 signaling pathway 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬IL-17 signaling pathway
|
Fontolizumab Fontolizumab 💬IL-17 signaling pathway
| Fontolizumab | 046 1件: 46 💬28. IL-17 signaling pathway
|
||||||||||||||||||||||||||||||||
29 | Inflammatory bowel disease 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬IL-17 signaling pathway
|
Emapalumab Emapalumab 💬Inflammatory bowel disease
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬29. Inflammatory bowel disease
|
||||||||||||||||||||||||||||||||
30 | Inflammatory bowel disease 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬IL-17 signaling pathway
|
Fontolizumab Fontolizumab 💬Inflammatory bowel disease
| Fontolizumab | 046 1件: 46 💬30. Inflammatory bowel disease
|
||||||||||||||||||||||||||||||||
31 | Inflammatory bowel disease 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Inflammatory bowel disease
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬31. Inflammatory bowel disease
|
||||||||||||||||||||||||||||||||
32 | Influenza A 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Influenza A
|
Emapalumab Emapalumab 💬Influenza A
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬32. Influenza A
|
||||||||||||||||||||||||||||||||
33 | Influenza A 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Influenza A
|
Fontolizumab Fontolizumab 💬Influenza A
| Fontolizumab | 046 1件: 46 💬33. Influenza A
|
||||||||||||||||||||||||||||||||
34 | Influenza A 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Influenza A
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬34. Influenza A
|
||||||||||||||||||||||||||||||||
35 | JAK-STAT signaling pathway 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬JAK-STAT signaling pathway
|
Emapalumab Emapalumab 💬JAK-STAT signaling pathway
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬35. JAK-STAT signaling pathway
|
||||||||||||||||||||||||||||||||
36 | JAK-STAT signaling pathway 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬JAK-STAT signaling pathway
|
Fontolizumab Fontolizumab 💬JAK-STAT signaling pathway
| Fontolizumab | 046 1件: 46 💬36. JAK-STAT signaling pathway
|
||||||||||||||||||||||||||||||||
37 | JAK-STAT signaling pathway 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬JAK-STAT signaling pathway
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬37. JAK-STAT signaling pathway
|
||||||||||||||||||||||||||||||||
38 | Kaposi sarcoma-associated herpesvirus infection 💬 1 gene, 1 drug (DrugBank) and 7 diseases |
IFNGR1 1件: IFNGR1 💬Kaposi sarcoma-associated herpesvirus infection
|
Interferon gamma-1b Interferon gamma-1b 💬Kaposi sarcoma-associated herpesvirus infection
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬37. JAK-STAT signaling pathway
|
||||||||||||||||||||||||||||||||
39 | Leishmaniasis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Leishmaniasis
|
Emapalumab Emapalumab 💬Leishmaniasis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬39. Leishmaniasis
|
||||||||||||||||||||||||||||||||
40 | Leishmaniasis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Leishmaniasis
|
Fontolizumab Fontolizumab 💬Leishmaniasis
| Fontolizumab | 046 1件: 46 💬40. Leishmaniasis
|
||||||||||||||||||||||||||||||||
41 | Leishmaniasis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Leishmaniasis
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬41. Leishmaniasis
|
||||||||||||||||||||||||||||||||
42 | Malaria 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Malaria
|
Emapalumab Emapalumab 💬Malaria
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬42. Malaria
|
||||||||||||||||||||||||||||||||
43 | Malaria 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Malaria
|
Fontolizumab Fontolizumab 💬Malaria
| Fontolizumab | 046 1件: 46 💬43. Malaria
|
||||||||||||||||||||||||||||||||
44 | Natural killer cell mediated cytotoxicity 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Malaria
|
Emapalumab Emapalumab 💬Natural killer cell mediated cytotoxicity
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬44. Natural killer cell mediated cytotoxicity
|
||||||||||||||||||||||||||||||||
45 | Natural killer cell mediated cytotoxicity 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Malaria
|
Fontolizumab Fontolizumab 💬Natural killer cell mediated cytotoxicity
| Fontolizumab | 046 1件: 46 💬45. Natural killer cell mediated cytotoxicity
|
||||||||||||||||||||||||||||||||
46 | Natural killer cell mediated cytotoxicity 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Natural killer cell mediated cytotoxicity
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬46. Natural killer cell mediated cytotoxicity
|
||||||||||||||||||||||||||||||||
47 | Necroptosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Necroptosis
|
Emapalumab Emapalumab 💬Necroptosis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬47. Necroptosis
|
||||||||||||||||||||||||||||||||
48 | Necroptosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Necroptosis
|
Fontolizumab Fontolizumab 💬Necroptosis
| Fontolizumab | 046 1件: 46 💬48. Necroptosis
|
||||||||||||||||||||||||||||||||
49 | Necroptosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Necroptosis
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬49. Necroptosis
|
||||||||||||||||||||||||||||||||
50 | Osteoclast differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Osteoclast differentiation
|
Emapalumab Emapalumab 💬Osteoclast differentiation
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬50. Osteoclast differentiation
|
||||||||||||||||||||||||||||||||
51 | Osteoclast differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Osteoclast differentiation
|
Fontolizumab Fontolizumab 💬Osteoclast differentiation
| Fontolizumab | 046 1件: 46 💬51. Osteoclast differentiation
|
||||||||||||||||||||||||||||||||
52 | Osteoclast differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Osteoclast differentiation
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬52. Osteoclast differentiation
|
||||||||||||||||||||||||||||||||
53 | Pathways in cancer 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Pathways in cancer
|
Emapalumab Emapalumab 💬Pathways in cancer
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬53. Pathways in cancer
|
||||||||||||||||||||||||||||||||
54 | Pathways in cancer 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Pathways in cancer
|
Fontolizumab Fontolizumab 💬Pathways in cancer
| Fontolizumab | 046 1件: 46 💬54. Pathways in cancer
|
||||||||||||||||||||||||||||||||
55 | Pathways in cancer 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Pathways in cancer
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬55. Pathways in cancer
|
||||||||||||||||||||||||||||||||
56 | PD-L1 expression and PD-1 checkpoint pathway in cancer 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬PD-L1 expression and PD-1 checkpoint pathway in cancer
|
Emapalumab Emapalumab 💬PD-L1 expression and PD-1 checkpoint pathway in cancer
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬56. PD-L1 expression and PD-1 checkpoint pathway in cancer
|
||||||||||||||||||||||||||||||||
57 | PD-L1 expression and PD-1 checkpoint pathway in cancer 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬PD-L1 expression and PD-1 checkpoint pathway in cancer
|
Fontolizumab Fontolizumab 💬PD-L1 expression and PD-1 checkpoint pathway in cancer
| Fontolizumab | 046 1件: 46 💬57. PD-L1 expression and PD-1 checkpoint pathway in cancer
|
||||||||||||||||||||||||||||||||
58 | PD-L1 expression and PD-1 checkpoint pathway in cancer 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬PD-L1 expression and PD-1 checkpoint pathway in cancer
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬58. PD-L1 expression and PD-1 checkpoint pathway in cancer
|
||||||||||||||||||||||||||||||||
59 | Proteasome 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Emapalumab Emapalumab 💬Proteasome
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬59. Proteasome
|
||||||||||||||||||||||||||||||||
60 | Proteasome 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Fontolizumab Fontolizumab 💬Proteasome
| Fontolizumab | 046 1件: 46 💬60. Proteasome
|
||||||||||||||||||||||||||||||||
61 | Rheumatoid arthritis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Emapalumab Emapalumab 💬Rheumatoid arthritis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬61. Rheumatoid arthritis
|
||||||||||||||||||||||||||||||||
62 | Rheumatoid arthritis 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Fontolizumab Fontolizumab 💬Rheumatoid arthritis
| Fontolizumab | 046 1件: 46 💬62. Rheumatoid arthritis
|
||||||||||||||||||||||||||||||||
63 | Systemic lupus erythematosus 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Emapalumab Emapalumab 💬Systemic lupus erythematosus
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬63. Systemic lupus erythematosus
|
||||||||||||||||||||||||||||||||
64 | Systemic lupus erythematosus 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Fontolizumab Fontolizumab 💬Systemic lupus erythematosus
| Fontolizumab | 046 1件: 46 💬64. Systemic lupus erythematosus
|
||||||||||||||||||||||||||||||||
65 | T cell receptor signaling pathway 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Emapalumab Emapalumab 💬T cell receptor signaling pathway
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬65. T cell receptor signaling pathway
|
||||||||||||||||||||||||||||||||
66 | T cell receptor signaling pathway 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Fontolizumab Fontolizumab 💬T cell receptor signaling pathway
| Fontolizumab | 046 1件: 46 💬66. T cell receptor signaling pathway
|
||||||||||||||||||||||||||||||||
67 | TGF-beta signaling pathway 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Emapalumab Emapalumab 💬TGF-beta signaling pathway
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬67. TGF-beta signaling pathway
|
||||||||||||||||||||||||||||||||
68 | TGF-beta signaling pathway 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Fontolizumab Fontolizumab 💬TGF-beta signaling pathway
| Fontolizumab | 046 1件: 46 💬68. TGF-beta signaling pathway
|
||||||||||||||||||||||||||||||||
69 | Th1 and Th2 cell differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Emapalumab Emapalumab 💬Th1 and Th2 cell differentiation
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬69. Th1 and Th2 cell differentiation
|
||||||||||||||||||||||||||||||||
70 | Th1 and Th2 cell differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Proteasome
|
Fontolizumab Fontolizumab 💬Th1 and Th2 cell differentiation
| Fontolizumab | 046 1件: 46 💬70. Th1 and Th2 cell differentiation
|
||||||||||||||||||||||||||||||||
71 | Th1 and Th2 cell differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Th1 and Th2 cell differentiation
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬71. Th1 and Th2 cell differentiation
|
||||||||||||||||||||||||||||||||
72 | Th17 cell differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Th17 cell differentiation
|
Emapalumab Emapalumab 💬Th17 cell differentiation
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬72. Th17 cell differentiation
|
||||||||||||||||||||||||||||||||
73 | Th17 cell differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Th17 cell differentiation
|
Fontolizumab Fontolizumab 💬Th17 cell differentiation
| Fontolizumab | 046 1件: 46 💬73. Th17 cell differentiation
|
||||||||||||||||||||||||||||||||
74 | Th17 cell differentiation 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Th17 cell differentiation
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬74. Th17 cell differentiation
|
||||||||||||||||||||||||||||||||
75 | Toxoplasmosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Toxoplasmosis
|
Emapalumab Emapalumab 💬Toxoplasmosis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬75. Toxoplasmosis
|
||||||||||||||||||||||||||||||||
76 | Toxoplasmosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Toxoplasmosis
|
Fontolizumab Fontolizumab 💬Toxoplasmosis
| Fontolizumab | 046 1件: 46 💬76. Toxoplasmosis
|
||||||||||||||||||||||||||||||||
77 | Toxoplasmosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Toxoplasmosis
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬77. Toxoplasmosis
|
||||||||||||||||||||||||||||||||
78 | Tuberculosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Tuberculosis
|
Emapalumab Emapalumab 💬Tuberculosis
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬78. Tuberculosis
|
||||||||||||||||||||||||||||||||
79 | Tuberculosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNG 1件: IFNG 💬Tuberculosis
|
Fontolizumab Fontolizumab 💬Tuberculosis
| Fontolizumab | 046 1件: 46 💬79. Tuberculosis
|
||||||||||||||||||||||||||||||||
80 | Tuberculosis 💬 3 genes, 3 drugs (DrugBank) and 12 diseases |
IFNGR1 2件: IFNGR1, IFNGR2 💬
|
Interferon gamma-1b Interferon gamma-1b 💬Tuberculosis
| Interferon gamma-1b | 018 7件: 18, 65, 85, 228, 299, 301, 326 💬80. Tuberculosis
|
||||||||||||||||||||||||||||||||
81 | Type I diabetes mellitus 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Type I diabetes mellitus
|
Emapalumab Emapalumab 💬Type I diabetes mellitus
| Emapalumab | 049 5件: 49, 54, 60, 65, 107 💬81. Type I diabetes mellitus
|
||||||||||||||||||||||||||||||||
82 | Type I diabetes mellitus 💬 1 gene, 2 drugs (DrugBank) and 6 diseases |
IFNG 1件: IFNG 💬Type I diabetes mellitus
|
Fontolizumab Fontolizumab 💬Type I diabetes mellitus
| Fontolizumab | 046 1件: 46 💬82. Type I diabetes mellitus
|
African trypanosomiasis
1 gene, 2 drugs (DrugBank) and 6 diseases
Allograft rejection
1 gene, 2 drugs (DrugBank) and 6 diseases
Amoebiasis
1 gene, 2 drugs (DrugBank) and 6 diseases
Antigen processing and presentation
1 gene, 2 drugs (DrugBank) and 6 diseases
Chagas disease
3 genes, 3 drugs (DrugBank) and 12 diseases
Cytokine-cytokine receptor interaction
3 genes, 3 drugs (DrugBank) and 12 diseases
Fluid shear stress and atherosclerosis
1 gene, 2 drugs (DrugBank) and 6 diseases
Graft-versus-host disease
1 gene, 2 drugs (DrugBank) and 6 diseases
Hepatitis C
1 gene, 2 drugs (DrugBank) and 6 diseases
Herpes simplex virus 1 infection
3 genes, 3 drugs (DrugBank) and 12 diseases
HIF-1 signaling pathway
3 genes, 3 drugs (DrugBank) and 12 diseases
IL-17 signaling pathway
1 gene, 2 drugs (DrugBank) and 6 diseases
Inflammatory bowel disease
3 genes, 3 drugs (DrugBank) and 12 diseases
Influenza A
3 genes, 3 drugs (DrugBank) and 12 diseases
JAK-STAT signaling pathway
3 genes, 3 drugs (DrugBank) and 12 diseases
Kaposi sarcoma-associated herpesvirus infection
1 gene, 1 drug (DrugBank) and 7 diseases
Leishmaniasis
3 genes, 3 drugs (DrugBank) and 12 diseases
Malaria
1 gene, 2 drugs (DrugBank) and 6 diseases
Natural killer cell mediated cytotoxicity
3 genes, 3 drugs (DrugBank) and 12 diseases
Necroptosis
3 genes, 3 drugs (DrugBank) and 12 diseases
Osteoclast differentiation
3 genes, 3 drugs (DrugBank) and 12 diseases
Pathways in cancer
3 genes, 3 drugs (DrugBank) and 12 diseases
PD-L1 expression and PD-1 checkpoint pathway in cancer
3 genes, 3 drugs (DrugBank) and 12 diseases
Proteasome
1 gene, 2 drugs (DrugBank) and 6 diseases
Rheumatoid arthritis
1 gene, 2 drugs (DrugBank) and 6 diseases
Systemic lupus erythematosus
1 gene, 2 drugs (DrugBank) and 6 diseases
T cell receptor signaling pathway
1 gene, 2 drugs (DrugBank) and 6 diseases
TGF-beta signaling pathway
1 gene, 2 drugs (DrugBank) and 6 diseases
Th1 and Th2 cell differentiation
3 genes, 3 drugs (DrugBank) and 12 diseases
Th17 cell differentiation
3 genes, 3 drugs (DrugBank) and 12 diseases
Toxoplasmosis
3 genes, 3 drugs (DrugBank) and 12 diseases
Tuberculosis
3 genes, 3 drugs (DrugBank) and 12 diseases
Type I diabetes mellitus
1 gene, 2 drugs (DrugBank) and 6 diseases